[6-K] Kazia Therapeutics Limited American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Schedule 13G Filing Overview: Tong Wu has filed a Schedule 13G indicating passive beneficial ownership of Armlogi Holding Corp. (CUSIP 042255109) common stock.

• Shares held: 3,460,000
• Ownership percentage: 8.2 % of the 42,250,934 shares outstanding as of 30 June 2025
• Voting & dispositive power: Sole power over all reported shares; no shared power
• Filing type: Rule 13d-1(c) passive investor report (Schedule 13G)
• Event date: 30 June 2025 Signature date: 09 July 2025

This filing signals that Mr. Wu has crossed the 5 % threshold and now ranks among the company’s largest shareholders. No additional transactions, purchase prices, or strategic intentions are disclosed, and the filer certifies the information as true and complete.

Positive

• Increased institutional-style stake may signal investor confidence and could enhance share-price stability through committed ownership.

Negative

• Ownership concentration gives a single investor significant voting influence, which could sway outcomes if future intent changes.

Insights

Securities Analyst

TL;DR: Passive 8.2 % stake adds notable shareholder but reveals no strategic plans—market impact likely modest.

The 13G shows Tong Wu controls 3.46 million shares, giving him a meaningful minority stake. Because it is a 13G (not 13D), he certifies no activist intent, suggesting a passive investment. The stake’s size could improve float stability and signal confidence in BTOC, yet without transaction data we cannot assess entry price or profitability. Overall, the filing is informational rather than transformative and should be viewed as neutral for valuation in the near term.

Corporate Governance Expert

TL;DR: New 8.2 % holder may influence governance voting; passive status limits immediate control risk.

An individual investor now owns over 8 % of outstanding shares with sole voting rights, potentially affecting shareholder meetings where attendance is low. However, by choosing Schedule 13G, Mr. Wu affirms no intent to direct company policy, merge, or seek board seats. Governance risk remains limited unless the filing is later amended to 13D. Investors should monitor future filings for shifts in intent or additional accumulation.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2025

Commission File Number 000-29962

 

 

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

 

 

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On July 9, 2025, Kazia Therapeutics Limited (the “Company”) issued a press release titled “Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial”. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company’s registration statements on Form F-3 (File No. 333-276091 and 333-281937).

EXHIBIT LIST

 

Exhibit	  	Description
99.1	  	Press Release of Kazia Therapeutics Limited dated July 9, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Kazia Therapeutics Limited (Registrant)

/s/ John Friend

John Friend

Chief Executive Officer

Date: 9 July 2025

FAQ

How many Armlogi (BTOC) shares does Tong Wu own?

He owns 3,460,000 common shares.

What percentage of Armlogi’s outstanding stock does this represent?

The stake equals 8.2 % of the 42.25 million shares outstanding.

Is Tong Wu acting as an activist investor?

No. The filing is on Schedule 13G, indicating a passive investment with no activist intentions disclosed.

Does Tong Wu share voting or dispositive power with others?

No. He has sole voting and dispositive power over all reported shares.

When did the ownership level that triggered this filing occur?

The reportable event date is 30 June 2025, with the filing signed on 09 July 2025.